ReproCELL Inkomsten in het verleden
Verleden criteriumcontroles 0/6
ReproCELL has been growing earnings at an average annual rate of 32.3%, while the Biotechs industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 21.1% per year.
Belangrijke informatie
32.3%
Groei van de winst
35.2%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 31.9% |
Inkomstengroei | 21.1% |
Rendement op eigen vermogen | -2.1% |
Nettomarge | -7.2% |
Volgende winstupdate | 13 Nov 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe ReproCELL geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 2,489 | -178 | 1,187 | 418 |
31 Mar 24 | 2,426 | -31 | 1,131 | 384 |
31 Dec 23 | 2,506 | -218 | 1,088 | 429 |
30 Sep 23 | 2,524 | -313 | 1,057 | 459 |
30 Jun 23 | 2,843 | -275 | 1,010 | 481 |
31 Mar 23 | 2,953 | -305 | 984 | 501 |
31 Dec 22 | 2,969 | -263 | 936 | 468 |
30 Sep 22 | 2,821 | -306 | 927 | 466 |
30 Jun 22 | 2,518 | -411 | 893 | 466 |
31 Mar 22 | 2,234 | -575 | 898 | 535 |
31 Dec 21 | 1,825 | -505 | 898 | 571 |
30 Sep 21 | 1,661 | -648 | 875 | 642 |
30 Jun 21 | 1,500 | -726 | 884 | 713 |
31 Mar 21 | 1,286 | -812 | 843 | 662 |
31 Dec 20 | 1,257 | -1,011 | 883 | 626 |
30 Sep 20 | 1,249 | -945 | 859 | 558 |
30 Jun 20 | 1,111 | -995 | 859 | 482 |
31 Mar 20 | 1,199 | -1,016 | 889 | 454 |
31 Dec 19 | 1,173 | -834 | 886 | 388 |
30 Sep 19 | 1,114 | -809 | 943 | 317 |
30 Jun 19 | 1,090 | -750 | 964 | 282 |
31 Mar 19 | 1,088 | -601 | 971 | 273 |
31 Dec 18 | 1,046 | -1,950 | 805 | 277 |
30 Sep 18 | 1,018 | -1,965 | 846 | 264 |
30 Jun 18 | 969 | -2,052 | 908 | 233 |
31 Mar 18 | 926 | -2,172 | 982 | 191 |
31 Dec 17 | 1,083 | -1,019 | 1,122 | 203 |
30 Sep 17 | 1,187 | -759 | 1,071 | 237 |
30 Jun 17 | 1,202 | -765 | 1,031 | 256 |
31 Mar 17 | 1,257 | -911 | 1,011 | 276 |
31 Dec 16 | 1,136 | -1,838 | 882 | 277 |
30 Sep 16 | 1,043 | -2,150 | 958 | 274 |
30 Jun 16 | 1,069 | -2,199 | 984 | 282 |
31 Mar 16 | 1,066 | -1,961 | 979 | 289 |
31 Dec 15 | 1,023 | -791 | 1,218 | 337 |
30 Sep 15 | 917 | -720 | 1,111 | 340 |
30 Jun 15 | 743 | -518 | 947 | 316 |
31 Mar 15 | 567 | -451 | 736 | 280 |
31 Dec 14 | 473 | -359 | 487 | 186 |
30 Sep 14 | 463 | -187 | 345 | 147 |
30 Jun 14 | 462 | -140 | 268 | 133 |
31 Mar 14 | 460 | -133 | 229 | 120 |
Kwaliteitswinsten: 4978 is currently unprofitable.
Groeiende winstmarge: 4978 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 4978 is unprofitable, but has reduced losses over the past 5 years at a rate of 32.3% per year.
Versnelling van de groei: Unable to compare 4978's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 4978 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Rendement op eigen vermogen
Hoge ROE: 4978 has a negative Return on Equity (-2.12%), as it is currently unprofitable.